Antiviral Agents (pharmacokinetics) < Antiviral Agents (pharmacology) < Antiviral Agents (physiology)

Facettes : AffPays.f Mesh.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 330.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000012 (2001)	C E Stephens [États-Unis] ; T M Felder ; J W Sowell ; G. Andrei ; J. Balzarini ; R. Snoeck ; E. De Clercq	Synthesis and antiviral/antitumor evaluation of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes and related compounds as a new class of diarylsulfones.
000037 (2003)	Martin Enserink ; Gretchen Vogel	Infectious diseases. Deferring competition, global net closes in on SARS.
000063 (2003)	Dennis Normile	Infectious diseases. Battling SARS on the frontlines.
000184 (2003)	J. Cinatl [Allemagne] ; B. Morgenstern ; G. Bauer ; P. Chandra ; H. Rabenau ; H W Doerr	Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.
000223 (2003)		SARS: What have we learned?
000266 (2003)	J. Cinatl [Allemagne] ; B. Morgenstern ; G. Bauer ; P. Chandra ; H. Rabenau ; H W Doerr	Treatment of SARS with human interferons.
000344 (2003)	Yossef Kliger [Israël] ; Erez Y. Levanon	Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.
000360 (2003)	Christopher Mcguigan [Royaume-Uni] ; Alison Jukes ; Sally Blewett ; Hubert Barucki ; Jonathan T. Erichsen ; Graciella Andrei ; Robert Snoeck ; Erik De Clercq ; Jan Balzarini	Halophenyl furanopyrimidines as potent and selective anti-VZV agents.
000383 (2003)	Guido Antonelli ; Carolina Scagnolari ; Elisa Vicenzi ; Massimo Clementi	Treatment of SARS with human interferons.
000420 (2003)	Ekachai Jenwitheesuk [États-Unis] ; Ram Samudrala	Identifying inhibitors of the SARS coronavirus proteinase.
000483 (2003)	Xiang Xu [République populaire de Chine] ; Yunqing Liu ; Susan Weiss ; Eddy Arnold ; Stefan G. Sarafianos ; Jianping Ding	Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
000618 (2004)	Jeffrey H. Toney [États-Unis] ; Sonia Navas-Martín ; Susan R. Weiss ; Andreas Koeller	Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design.
000683 (2004)	Lisa E. Hensley [États-Unis] ; Elizabeth A. Fritz [États-Unis] ; Peter B. Jahrling [États-Unis] ; Christopher Karp [États-Unis] ; John W. Huggins [États-Unis] ; Thomas W. Geisbert [États-Unis]	Interferon-β 1a and SARS Coronavirus Replication
000698 (2004)	Ute Ströher [Canada] ; Antonino Dicaro [Italie] ; Yan Li [Canada] ; James E. Strong [Canada] ; Fred Aoki [Canada] ; Frank Plummer [Canada] ; Steven M. Jones [Canada] ; Heinz Feldmann [Canada]	Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α
000714 (2004)	Kenneth Tsang [République populaire de Chine] ; Wing-Hong Seto	Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment.
000748 (2004)	Xue Wu Zhang [République populaire de Chine] ; Yee Leng Yap	Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design.
000813 (2004)	Norio Yamamoto [Japon] ; Rongge Yang [Japon] ; Yoshiyuki Yoshinaka [Japon] ; Shinji Amari [Japon] ; Tatsuya Nakano [Japon] ; Jindrich Cinatl [Allemagne] ; Holger Rabenau [Allemagne] ; Hans Wilhelm Doerr [Allemagne] ; Gerhard Hunsmann [Allemagne] ; Akira Otaka [Japon] ; Hirokazu Tamamura [Japon] ; Nobutaka Fujii [Japon] ; Naoki Yamamoto [Japon]	HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
000821 (2004)	Martin Enserink	Infectious diseases. One year after outbreak, SARS virus yields some secrets.
000836 (2004)	Tobias Hertzig [Allemagne] ; Elke Scandella [Suisse] ; Barbara Schelle [Allemagne] ; John Ziebuhr [Allemagne] ; Stuart G. Siddell [Royaume-Uni] ; Burkhard Ludewig [Suisse] ; Volker Thiel [Suisse]	Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA.
000841 (2004)	Guan-Hua Du [République populaire de Chine] ; Wei Wang ; Ke-Di Cheng ; Li-Li Cao ; Xiu-Ying Yang ; Ping Zhu	[Targets and studies on anti-SARS drugs].
000886 (2004)	Emily L. C. Tan [Singapour] ; Eng Eong Ooi [Singapour] ; Chin-Yo Lin [Singapour] ; Hwee Cheng Tan [Singapour] ; Ai Ee Ling [Singapour] ; Bing Lim [Singapour] ; Lawrence W. Stanton [Singapour]	Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Antiviral Agents (pharmacology)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Antiviral Agents (pharmacology)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antiviral Agents (pharmacology)
}}

---

This area was generated with Dilib version V0.6.33. Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021